IBRX — ImmunityBio, Inc.

ImmunityBio Q4 2025 Earnings Call Summary

1. Key Financial Results and Metrics:

• Full year net product revenue for ANKTIVA reached $113 million, a 700% increase from $14.1 million in 2024.
• Unit sales volume increased by 750% year-over-year.
• Q4 revenue was $38.3 million, reflecting a 20% increase from Q3.
• Full year R&D expenses were $218.6 million, up from $190.2 million in 2024, driven by clinical trial and manufacturing costs.
• SG&A expenses decreased to $150 million from $168.8 million in 2024.
• Net loss attributable to common stockholders was $351.4 million, down from $413.6 million in 2024.
• Cash, cash equivalents, and marketable securities totaled $242.8 million as of December 31, 2025.

2. Strategic Updates and Business Highlights:

• ANKTIVA is now authorized in 33 countries, including major markets like the U.S., U.K., Saudi Arabia, and the EU.
• The company has partnered with Accord Healthcare for European commercialization, leveraging their established infrastructure for market access.
• ImmunityBio received two approvals in Saudi Arabia: one for bladder cancer and another for lung cancer, marking a significant expansion of ANKTIVA's application.
• The company is addressing the ongoing BCG shortage with an FDA-authorized expanded access program for recombinant BCG.
• ImmunityBio is advancing its AI-driven robotic cellular manufacturing capabilities, enhancing production efficiency for NK cell therapies.

3. Forward Guidance and Outlook:

• ImmunityBio is focused on expanding its commercial footprint, particularly in the U.S. and Europe, with plans to prioritize the five largest EU markets for ANKTIVA.
• The company aims to submit a BLA for the BCG-naive indication in Q4 2026, which could significantly broaden its addressable market.
• Continued growth is expected as awareness of ANKTIVA increases among healthcare providers.

4. Bad News, Challenges, or Points of Concern:

• The company faces ongoing challenges related to the BCG shortage, which could impact patient access to treatment.
• There is a significant net loss still reported, indicating the need for sustained revenue growth to achieve profitability.
• Regulatory hurdles remain, as evidenced by the FDA's request for additional data before approving certain indications.
• Competitive pressures from established players in the immunotherapy space could pose challenges to market penetration.

5. Notable Q&A Insights:

• Dr. Soon-Shiong discussed the plausible mechanism of action pathway, emphasizing that ANKTIVA's pharmacological effects align with biological plausibility, which could facilitate accelerated approvals.
• The company is exploring the combination of ANKTIVA with checkpoint inhibitors, with the potential for significant survival benefits in patients previously treated with these therapies.
• ImmunityBio is strategically avoiding partnerships with Big Pharma to maintain control over its innovative approach to cancer treatment, focusing on a holistic view of the immune system rather than isolated therapies.
• The QUILT-3.055 study, which combines ANKTIVA with checkpoint inhibitors, has treated 147 patients, comparable to previous single-arm studies that led to FDA approvals for other therapies.

This comprehensive summary encapsulates the key financial metrics, strategic initiatives, forward-looking statements, challenges, and insights from the Q&A session, providing a balanced overview of ImmunityBio's current status and future direction.